Bushveld Minerals Limited (LON:BMN) delivered a robust performance in the face of weaker vanadium prices that left it in a strong financial position moving into the second half.

Synairgen PLC (LON:SNG), the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate.

Columbus Energy Resources PLC (LON:CERP) told investors that its plan to drill the Saffron prospect has been approved by Trinidad’s Ministry of Energy and Energy Industries.

Arix Bioscience PLC (LON:ARIX) said it co-led a €20mln series-A investment round in a spin-out from Aarhus University, Denmark, that further strengthens its position in oncology.

Oriole Resources PLC (LON:ORR) is expanding its footprint in Cameroon, following early success at the Bibemi and Wapouzé gold projects where it is earning up to a 90% interest.

Alba Mineral Resources plc (LON:ALBA) will be keenly watching progress at the Horse Hill oil project, onshore southern England, where drilling has now begun for a horizontal well.

Katoro Gold PLC (LON:KAT) has extended the timeframe around the proposed sale of its Imweru gold project in Tanzania to Lake Victoria Goldfields.

Thor Mining PLC (LON:THR)(ASX:THR) has noted the publication of a maiden resource for the Big Sandy lithium deposit in Arizona.

Vast Resources PLC (LON:VAST) said it is “near to finalisation” on documentation for enough funding to cover commissioning at the Baita Plai polymetallic mine in Romania and to begin diamond mining in Zimbabwe.

I3 Energy Plc’s (LON:i3E) first half results highlight ‘an incredibly active period’, according to chief executive, Majid Shafiq.

KR1 PLC (LON:KR1) reported a £4.6mln unrealised profit from the increase in the value of its portfolio of cryptocurrency assets in the first half of the year despite a volatile period for the market.

IronRidge Resources Ltd (LON:IRR) said it has an “exciting year” ahead as it makes progress at its exploration projects in Africa and Australia.

Live Company Group PLC’s (LON:LVCG) profits will be “heavily weighted” to the second half of the year said chairman David Ciclitira.

Rose Petroleum PLC (LON:ROSE) chief executive Colin Harrington told investors he is excited about the next steps in the group’s transformation.

Victoria Oil & Gas PLC’s (LON:VOG) half yearly numbers revealed a substantial improvement, as expected, thanks to the restart of sales to its key customer, a neighbouring gas-fired power plant.

Echo Energy PLC (LON:ECHO) interim results statement highlights a successful restructuring over what’s described as “a period of change”.

Ariana Resources PLC (LON:AAU) expects to reveal “in due course” its plans for Cyprus, where it has been carrying out due diligence on a potential exploration portfolio.

IOVLabs, the parent company of RSK, in which Coinsilium Group Limited (NEX:COIN) has a stake, has acquired Taringa, the world’s largest Spanish-speaking social network platform.

Immupharma PLC (LON:IMM) remains upbeat there are still commercial avenues open for its lupus treatment Lupuzor.

Advanced Oncotherapy PLC (LON:AVO) has bumped up the size of an open offer by 16% as investors clamoured for shares in the proton beam therapy specialist.

Europa Metals Ltd (LON:EUZ) said it had raised £1mln in an over-subscribed issue of stock at 0.025p a share.

Synthetic fuels firm Quadrise Fuels International PLC (LON:QFI) said its recent open offer received a take-up of 74.8%.

Savannah Resources PLC (LON:SAV) has confirmed that major shareholder Al Marjan has now bought £1.24mln of shares as part of a £5mln fundraising.

CentralNic Group PLC’s (LON:CNIC) senior secured bond of €50mln was admitted to trading on the Oslo Stock Exchange on Friday, with a coupon of three-month EURIBOR plus 7% per year.

MaxCyte Inc (LON:MXCT) said it is taking part in five industry conferences at which it will showcase its CARMA technology.

Faron Pharmaceuticals Oy (LON:FARN) gave a poster presentation at the European Society of Medical Oncology over the weekend, showcasing recent data from its ongoing MATINS study, where good tolerability has so far been seen and “promising” anti-tumour activity.

Amryt Pharma PLC (LON:AMYT) will attend eight investor and healthcare industry events in the coming two months, including the Cantor Fitzgerald Global Healthcare Conference in New York, the Proactive Investors One2One Investor Forum and the Jefferies Global Healthcare Conference, both in London.